共 60 条
- [5] [Anonymous], 2023, Global strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease
- [6] [Anonymous], Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
- [7] [Anonymous], 2017, Phosphodiesterase 3 and 4 inhibitors in chronic obstructive pulmonary disease
- [8] [Anonymous], 2022, Ensifentrine (RPL554) in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled phase 3 trial
- [9] [Anonymous], 2018, Dual Phosphodiesterase 3 and 4 Inhibitors: A New Therapeutic Approach For Chronic Obstructive Pulmonary Disease
- [10] Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials) [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (04) : 406 - 416